title: Targeting solid tumours with potassium channel activators. A return to fundamentals?
abstract: From a pharmacological point of view nicotinamide and minoxidil are potassium channel activators. Nicotinamide is used as a radiosensitizer in ARCON (accelerated radiotherapy combined with carbogen breathing and nicotinamide) therapeutic strategy with promising results but not confirmed so far. Minoxidil has never been considered by radiotherapists. Based from recent pathophysiological considerations we suggest a new perspective for the use of these two "old" molecules in order to target solid tumours.
authors.forename: Philippe
authors.initials: P
authors.lastname: Trechot
mesh_terms: D006801:Humans; D008914:Minoxidil / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends*; D009369:Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000627:therapeutic use*; D015221:Potassium Channels / Q000819:agonists*
chemical_list: D015221:Potassium Channels; D009536:Niacinamide; D008914:Minoxidil